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1 Introduction
In previous studies we have demonstrated a
difference in the mode of action of prostaglan-
din E2 versus oxytocin during induced parturi-
tion: prostaglandin Ei gave a slower onset of
contractions [2] and induced a parturition time
dependent decrease in maternal serum prolactin
levels [3]. Prostaglandin p2a elevates maternal
serum prolactin concentrations [7] and is a po-
tent stimulator of uterine contractions [5]. Some
investigators suggest that prostaglandin Fia is
formed in the uterus during contractions [16,
17,28]. If this prostaglandin reaches the circula-
tion one would expect an increase in maternal
serum prolactin. However, the scarce data
available from spontaneous labor rather indi-
cate a decrease in serum prolactin during partu-
rition [9, 15, 31, 32].
For reasons discussed in detail by GRANSTRÖM
et al. [14], primary prostaglandins cannot be
measured accurately in blood plasma samples.
The major PGE2 metabolite, 15-keto-13,14-di-
hydroprostaglandin Ei, is rearranged and its
analysis requires special conditions [13]. The
corresponding PGF2a metabolite, 15-keto-
13,14-dihydroprostaglandin F2a, can be deter-
mined in plasma and reflects the formation
of F-prostaglandins [12]. Accordingly, it was
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selected for assay in the present communica-
tion. To explore whether changes in 15-keto-
13,14-dihydroprostaglandin F2a levels in ma-
ternal blood during induced parturition are re-
lated to serum prolactin changes, the present
study was undertaken.
2 Materials and methods
The study comprised 83 healthy women in
whom labor was induced mainly for reasons of
post-datism (table I). All patients had a vertex
presentation and a normal pelvic outlet.
Patients with toxemia of pregnancy treated with
more than 100 mg hydralazine (Apresoline®,
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Sex of neonate (?/<})
Apgar score at Υ





































Data in the table are mean values and ranges.
CIBA) and/or 1 g chlortiazide (Chlortride®,
MSD) daily were excluded from the study, as
were patients with any other disease.
Labor was induced by low amniotomy and
intravenous infusion of oxytocin (Syntocinon®,
Sandoz) in 5.5% glucose, starting at 8.30 a.m.
with 5 mlU/min and increasing over three
hours to a maximum of 20 mlU/min; or by low
amniotomy and oral administration of PGEi
(Upjohn Co., Kalamazoo, Mich., USA): dosage
0.5 mg initially, followed by 1.0 mg every hour
until delivery. Treatment was randomized. The
registration of uterine contractility was done
with external and internal tocography accord-
ing to established procedures [27]. Start of labor
was defined as the time when three contractions
with an amplitude of more than 25 mm Hg
Table II. 15-keto-13,14-dihydro-PGF2a and prolactin in maternal blood during prostaglandin E2 (PGE2) or oxytocin
therapy for labor induction. Mean values; 95% confidence limits.
Labor stage
Start of treatment
Immediately5) prior to the delivery
15-ketodihydro-PGF2a (pmol/1)





























!) Paired t-test; t = -10.49 p < 0.001
2) Paired t-test; t = -5.70 p < 0.001
Contrast between 1) and 2): t = 2.23, p = 0.03.
Tested contrast: Diff (15-ketodihydro-PGF2a) PG - Diff (15-ketodihydro-PGF2a) OXY
3) Paired t-test; t = 3.90 p < 0.001
4) Paired t-test; t = 2.52 p = 0.017
Contrast between 3) and 4): t = 1.54, p = 0.13.
Tested contrast: Diff (prolactin) PG - Diff (prolactin) OXY
5) Time difference (mean and ranges) between blood sample and parturition: in PGE2 treated patients 33 (4—60)
minutes; in oxytocin treated patients 34 (2 — 60) minutes.
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were registered during 10 minutes [6]. The two
patient categories were given the same type
of analgesic treatment. Demerol® (Meperidine,
Pethidine) 100 mg i. m. (AGO, Sweden), was
administerd to 23 PGEi and to 29 oxytocin
treated women. Epidural analgesia (bupivac-
aine-Marcaine®, Bofors, Sweden) was given to
12 PGE2 and to 8 oxytocin treated patients,
respectively.
Blood samples were drawn from the antecubital
vein at the start of treatment, one hour into
treatment, immediately prior to delivery and
after delivery. Mixed umbilical blood was col-
lected at parturition by section of the cord.
Serum and plasma were isolated by centrifuga-
tion and stored at — 20 °C until analyzed. The
number of individuals from whom a complete
set of analyzes could be obtained was few.
Therefore, the results given in tables II to IV
refer to patients in whom the appropriate sam-
ples were obtained to allow intra-patient com-
parisons.
Table ΙΠ. 15-keto-13,14-dihydro-PGF2a and prolactin in maternal blood during prostaglandin £2 (PGE2) or oxyto-
cin therapy for induction of labor. Mean values; 95% confidence limits.
Labor stage 15-ketodihydro-PGF2a (pmol/1) Prolactin
PGE2 (n = 16) Oxytocin (n = 19) PGE2 (n = 24) Oxytocin (n = 20)
Immediately1) prior to delivery














*) Time difference, mean and range, between blood sample and delivery: 33 (4—60) minutes (PGE2), and 34 (2 — 60)
minutes (oxytocin).
2) Time difference, mean and range, between blood sample and delivery: 38 (2 — 60) minutes (PGE2), and 39 (2 — 60)
minutes (oxytocin).
3) Independent t-test: p = 0.001.
4) Independent t-test: p = 0.016.
Table IV. 15-keto-13,14-dihydro-PGF2a and prolactin concentrations in blood in connection with partus induced
by prostaglandin £2 (PGE2) or oxytocin. Mean values; 95% confidence limits.
Labor stage 15-ketodihydro-PGF2a (pmol/1) Prolactin
Immediately prior to delivery
PGE2 (n = 15) Oxytocin (n = 13)
1870 1058
(1467-2383) (714-1568)












1) Paired t-test; t = -4.63 (p < 0.001).
2) Paired tested; t = -5.57 (p < 0.001).
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Radioimmunoassay (RIA) of serum samples
was performed in duplicate with commercial
kits from Serono Diagnostics (prolactin) and
Diagnostic Products Corp. (cortisol). Intraas-
say and interessay coefficients of variation were
all below 10%. Levels of 15-ketodihydro-
PGF2a in plasma were determined by RIA as
described in detail previously [12]. Specificity
of the employed antiserum and accuracy data
have been reported previously [26].
The study also included eight non-pregnant
healthy women with normal menstrual cycles.
These women were given a single dose of 0.5
mg PGE2 orally. Blood was sampled after 10,
20, 30, 60 and 90 minutes. Levels of 15-ketodi-
hydro-PGFia were determined as described
above.
Statistical methods: Calculations were pro-
formed on the logarithms of the measured va-
lues. Two-tailed 95% conficence intervals of
the mean in terms of logarithmic values were
calculated. Probability values (p-values) were
determined in two-tailed tests. Geometric
means and interval limits were obtained from
the antilogarithms. When variances of two
groups differed significantly, a separate vari-
ance estimate of Student's t-statistic was used,
otherwise a pooled variance estimate, to test
whether the means of the groups differed or
not. Contrasts of means between more than
two groups were also calculated. Student's t-
statistic was used to test whether the formed
contrasts differed from expectancy.
3 Results
The changes in maternal serum hormone levels
during induced parturition are displayed in
table II. Oxytocin and PGEi caused similar
elevations in maternal serum cortisol (data not
shown): whereas, decreases in the levels of pro-
lactin seemed more pronounced in the PGE2
group (table II). The changes observed in 15-
ketodihydro-PGFia throughout parturition
were highly significant in both treatment
groups. The PGEi group showed a significantly
higher increase than the oxytocin group.
In terms of onset of contractions, the median
time for women in the PGEi group was 62
minutes and for women in the oxytocin group
45 minutes (p = 0.004; median test). The total
time to delivery did not differ between the
groups (table I). If onset of contractions is
related to elevation of 15-ketodihydro-PGF2a,
this should be reflected one hour into treat-
ment. Among women receiving oxytocin, the
15-ketodihydro-PGF2a level changed from 315
pmol/1 (226-439) to 361 pmol/1 (264-494)
during the first hour of treatment (n = 31).
This increase is not significant. In the PGE2
group (n = 31) the corresponding figures were
396 pmol/1 (282-556) and 821 pmol/1
(614-1096). The elevation in the PGE2 group
is highly significant (p < 0.001; paired t-test).
Tested for the contrast between the PGE2 and
oxytocin groups, a significant difference was
found (p < 0.001), i.e. the elevation in the
PGE2 group was significantly higher than in
the oxytocin group.
Following delivery, there was still a difference
between PGE2 and oxytocin treated women in
terms of 15-ketodihydro-PGF2a levels in ma-
ternal plasma; whereas, no significant differ-
ence was seen either in prolactin (table III) or
in cortisol concentrations (data not shown).
The level of 15-ketodihydro-PGF2a in the mixed
umbilical plasma in each treatment group was
almost the same as in the maternal plasma
immediately prior to delivery. When the two
experimental groups were compared for hor-
mone levels in mixed umbilical blood (table IV),
a clearly significant difference was observed in
15-ketodihydro-PGF2a concentration but not
in prolactin.
The non-pregnant women responded to oral
PGE2 with an increase in levels of 15-keto-
13,14-dihydro-PGF2a which was already signifi-
cant at 10 (p = 0.034; Wilcoxon) and 20 min-
utes (p = 0.012; Wilcoxon) after PGE2 adminis-
tration. The mean basal level was 160 pmol/1
(129-218) and after PGE2 administration 228
pmol/1 (118-297) and 440 pmol/1 (213-907)
at 10 and 20 minutes, respectively. One hour
after treatment the average concentration was
476 pmol/1 (324 — 605), i.e. no significant in-
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Figure 1. Plasma levels of 15-keto-13,14-dihydro-PGF2a
(geometric mean; 95% confidence limits for geometric
mean) following a single oral dose of 0.5 mg PGE2 in
eight healthy non-pregnant female volunteers.
crease occurred between 20 and 60 minutes.
None of the women experienced uterine con-
tractions or complained of abnormal pain and
after 90 minutes the average plasma level was
still elevated, i.e. 543 pmol/l (409-789)
(figure 1).
4 Discussion
The present report shows that oral PGE2 treat-
ment leads to increases in the plasma content
of 15-ketodihydro-PGF2a that are clearly above
the levels induced by oxytocin and reportedly
at hand during spontaneous labor [29, 36]. Yet,
contractions appeared later in the PGEz treated
group. The average time before contractions
appeared in the PGE2 treated pregnant women
was 62 minutes. The women receiving oxytocin
had a mean time to onset of contractions of 45
minutes but no increase in plasma concentra-
tions of 15-ketodihydro-PGF2a at 60 minutes.
From two hours into treatment to the time
immediately before parturition there was no
significant difference in the increase in plasma
15-ketodihydro-PGF2a between PGE2 and oxy-
tocin treated women. Thus, the present study
fails to relate increases in plasma levels of 15-
ketodihydro-PGF2a to onset of uterine contrac-
tions [10, 21]. Nor was it possible to find a
relation between the plasma concentration of
the metabolite and delivery time [33]. The trig-
gering of contractions may have been mediated
by amniotomy and the locally formed prosta-
glandins may not have been reflected in the
circulation [34, 35]. Once labor had been estab-
lished, increases in plasma 15-ketodihydro-
PGF2a levels were similar in PGE2 and oxytocin
treated women. In spontaneous labor it has
been reported that 15-ketodihydro-PGF2a in-
creased in parallel with cervical dilatation [16,
24], possibly reflecting formation of uterine
PGP2a. However, it has been questioned
whether local formation of PGF2a in the uterus
is soon reflected by 15-ketodihydrp-PGF2a in
plasma [25, 30]. Oral PGE2 obviously led to an
increase in plasma levels of 15-ketodihydro-
PGP2a. A possible explanation is that PGE2
itself may be converted to PGF2a in the course
of, or following, absorption [8, 18, 19, 20] and
later be metabolized into 15-ketodihydro-
PGP2a. This metabolite lacks biological activity
and cannot be related as such to the clinical
events or to prolactin levels. Thus, high levels
of this metabolite caused by exogenous PGE2
will shadow an endogenous production. Also in
the case of non-pregnant women, a significantly
elevated level of 15-ketodihydro-PGF2a metab-
olite is seen 20 minutes after oral PGE2. The
levels remained high for as long as 90 minutes
and, considering the short half-lives of PGE2
and PGF2a as well as of 15-ketodihydro-PGF2a
in the circulation, it seems likely that exogenous
PGE2 is not only converted to PGF2a but may
also have induced an ongoing endogenous
prostaglandin — i.e. PGF2a — biosynthesis,
perhaps in the uterus. An alternative hypothesis
for our findings is that an excess of PGE2 and
its circulating metabolites could well overload
enzyme systems to such an extent that this
results in a longer circulating half-life of the
PGF2a metabolites [11].
Since PGF2a and PGE2 exert antagonistic
effects on prolactin levels in pregnant women
[4, 7], the lowering of prolactin during oral
PGE2 therapy indicates that PGE2 effects domi-
nate over PGF2a effects, even though £2 to
J. Perinat. Med. 15 (1987)
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some extent is converted to PGFia or induces
PGFia biosynthesis. Since the stress of labor
measured as serum cortisol (data not shown)
was the same in both oxytocin and PGE2
treated women, this factor is likely not directly
involved in prolactin release, as previously sug-
gested [38].
The possibility exists that the epidural analgesia
might have influenced circulating prolactin and
15-ketodihydro-PGF2a levels [22, 23, 37]. But
the relative frequency of this therapy was very
similar in the two treatment groups. It is thus
less likely that epidural analgesia influenced our
results.
About half an hour after delivery, maternal
serum prolactin levels were the same in both
treatment groups, indicating that the PGEi in-
duced effects on maternal pituitary prolactin
release had stopped or been counteracted.
However, 1 S-ketodihydro-PGFia levels were at
least as high some 30 minutes after as before
delivery, which makes it less likely that 15-
ketodihydro-PGF2a in itself participates in ma-
ternal pituitary prolactin release. The levels of
15-ketodihydro-PGF2a in the mixed umbilical
cord blood seem to be close to the maternal
plasma concentration in both treatment groups.
Since there is no artero-venous difference in
umbilical blood for 15-ketodihydro-PGF2a [1],
a maternal origin for the 15-ketodihydro-
PGF2<x measured in mixed umbilical blood may
be suggested. The data also indicate that the
placenta does not metabolize 15-ketodihydro-
PGF2a to any major extent.
In conclusion, our data show that there was
no correlation between 15-keto-13,14-dihydro-
PGF2a concentration and onset of contraction
or labor time in either the PGE2 or the oxytocin
treated group. The higher values of plasma 15-
keto-13,14-dihydro-PGF2a in women receiving
PGE2 tablets as compared to those treated with
oxytocin suggest that exogenous PGE2 is to
some extent reduced to PGF2a. Such a reduc-
tion seems also to take place in non-pregnant
women, in whom administration of oral PGE2
gave rise to marked increases in plasma 15-
keto-13,14-dihydro-PGF2a. The marked de-
crease in serum prolactin in the PGE2 treated
pregnant women, which normalized following
parturition, suggests a PG involvement in
serum prolactin control.
Summary
15-keto-13,14-dihydroprostaglandin p2a plasma levels
were measured in pregnant women following labor in-
duction with either oral PGE2 treatment or intravenous
oxytocin, both combined with amniotomy. The median
time to start of contractions was 62 minutes in the PGE2
treated group and 45 minutes in the oxytocin treated
group (p < 0.01; median test). The increase in 15-
ketodihydro-PGF2a appeared earlier in the PGEa group
but not in the oxytocin group (p < 0.001 and p =
0.210, respectively). At delivery, the 15-ketodihydro-
PGF2a values had further increased in both treatment
groups. The increase was significantly higher in the
PGE2 treated patients compared with oxytocin treated
patients (p = 0.03; contrast test). Despite higher 15-
ketodihydro-PGF2a concentrations throughout parturi-
tion, PGE2 women did not deliver more rapidly than
oxytocin infused women. There was no correlation be-
tween 15-ketodihydro-PGF2a blood concentrations and
either onset of contrations or labor time. The decrease
in maternal serum prolactin concentration during partu-
rition was pronounced (p < 0.001) in the PGE2 group
but occurred also in oxytocin treated patients
(p < 0.02). A single oral dose (0.5 mg) of PGE2 taken
by non-pregnant women led to significant (p < 0.05)
increases in 15-ketodihydro-PGF2a levels in blood
plasma after 10 minutes. This increase persisted for at
least 90 minutes. It is suggested that oral PGE2 may
be transformed into PGF2a and/or induce endogenous
PGF2a biosynthesis.
Keywords: Cord blood, labor induction, maternal blood, prolactin, 15-keto-13,14-dihydroprostaglandin
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Zusammenfassung
15-Ketodihydro-PGF2a- und Prolaktinspiegel im mütter-
lichen Serum und Nabelvenenblut während der Geburtsein-
leitung mit Prostaglandin £2 oder Oxytozin
Wir bestimmten die Plasmaspiegel von 15-Keto-13,14-
dihydroprostaglandin F2a bei schwangeren Frauen nach
Geburtseinleitung mit oraler PGEi-Gabe bzw. intrave-
nöser Oxytozingabe und arteflzieller Blaseneröffnung.
In der PGEz-Gruppe setzten die Wehen nach durch-
schnittlich 62 Minuten ein, in der Oxytozingruppe nach
45 Minuten (p < 0.01; Mediantest). In der PGE2-
Gruppe kam es früher zu einem Anstieg des 15-Ketodi-
hydro-PGFza. Eine Stunde nach Behandlungsbeginn war
der PGFia-Spiegel in der PGEi-Gruppe signifikant er-
höht, nicht aber in der Oxytozingruppe (p < 0.001
versus p = 0.210). Zum Zeitpunkt der Geburt waren die
15-Ketodihydro-PGF2a-Werte in beiden Gruppen weiter
angestiegen, wobei der Anstieg in der PGE2-Gruppe
signifikant größer war als in der Oxytozingruppe (p =
0.03 bei Gegenüberstellung). Trotz höherer 15-Ketodihy-
dro-PGF2a-Konzentrationen in der PGE2-Gruppe war
der Geburtsverlauf hier nicht kürzer als in der Oxytozin-
gruppe. Die Höhe des 15-Ketodihydro-PGP2a-Spiegels
im Blut und das Einsetzen bzw. die Geburtsdauer korre-
lierten nicht miteinander. Der Abfall des Serumprolak-
tins war unter der Geburt in der PGE2-Gruppe beson-
ders ausgeprägt (p < 0.001), zeigte sich aber auch in
der Oxytozingruppe (p < 0.02). Eine einmalige Gabe
von 0,5 mg PGE2 an nichtgravide Frauen führte nach
10 Minuten zu einem signifikanten Anstieg des 15-Keto-
dihydro-PGF2a (p < 0.05), das über mindestens 90
Minuten erhöht blieb. Wir meinen, daß oral verabreich-
tes PGE2 zu PGF2a metabolisiert wird und/oder die
endogene PGF2a-Biosynthese induziert.
Schlüsselwörter: Geburtseinleitung, Nabelschnurblut, mütterliches Serum, Prolaktin, 15-Keto-13,14-dihydropro-
staglandin F2a-
Resume
Taux de 15-ceto-13,14 dihydroprostaglandine Fza et de
prolactine dans le sang maternel et dans le sang du cordon
lors des declenchements du travail par prostaglandine £2
ou par ocytocine
On a mesure les taux plasmatiques de 15-13,14 di-
hydroprostaglandine F2a chez des femmes enceintes
apres induction tu travail avec soit PGE2 per os soit
ocytocine intra-veineuse, les deux methodes etant asso-
ciees ä la rupture des membranes. Le delai moyen du
debut des contractions a ete de 62 minutes dans le
groupe traite par prostaglandines et de 45 minutes pour
le goupe traite par ocytocine (p < 0,01). L'elevation
des 15-cetodihydro-PGF2a est apparue plus tot chez les
femmes traitees par PGE2. Au bout d'une heure de
traitement Faugmentation etait significative dans le
groupe PGE2 mais pas dans le groupe ocytocine ( P <
0,001 et p = 0,210, respectivement). Au moment de
Paccouchement, les valeurs de PGF2a se sont encore plus
elevees et celä dans les deux groupes. L'elevation a ete
de fagon significative plus importante dans le groupe
PGE2 que dans le groupe ocytocine (p = 0,03). Malgre
des taux de 15-cetodihydro PGF2a plus eleves tout au
long de 1'accouchement les femme sous PGE2 n'accou-
chent pas plus rapidement que les femmes sous perfusion
d'ocytocine. II n'y a pas de correlation entre les concen-
trations seriques de 15-cetodihydro PGF2a ni avec le
debut des contractions ni aved la duree du travail. La
diminution des taux maternels de Prolactine serique au
cours de 1'accouchement est nette (p < 0,001) dans le
groupe PGE2 mais existe egalement chez les patientes
sous ocytocine (p < 0,02). Une dose orale unique (0,5
mg) de PGE2 prise par une femme non enceinte entraine
une augmentation significative (p < 0,05) des 15-
cetodihydro-PGP2a plasmatiques au bout de 10 minutes.
Cette augmentation persiste au moins 90 minutes. Les
auteurs suggerent que les PGE2 orales peuvent etre trans-
formees en PGF2a et/ou induire la Synthese de PGF2
endogenes.
Mots-cles: Declenchement du travail, prolactine, sang du cordon, sang maternel, 15-ceto-13,14-dihydroprostaglan-
dine, p2a-
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